Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

(marketscreener.com) Clinical data in nine cancer indications from trial with 264 patients accruedPlenary discussion relating to expansion cohorts represent heavily pretreated patientsAdditional SITC presentations cover 1) botensilimab’s differentiated mechanism; 2) Phase 2 trial of anti-CD73-TGFβ-trap bifunctional antibodyDhan Chand, PhD,...https://www.marketscreener.com/quote/stock/AGENUS-INC-8290/news/Agenus-to-Present-Botensilimab-Data-at-a-Plenary-Session-of-the-Society-for-Immunotherapy-of-Cancer-41932861/?utm_medium=RSS&utm_content=20221005